Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis
- PMID: 24566842
- PMCID: PMC3958815
- DOI: 10.1007/s40265-014-0191-y
Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis
Abstract
Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease. Up to 40 % of patients with psoriasis will go on to develop PsA, usually within 5-10 years of cutaneous disease onset. Both conditions share common pathogenic mechanisms involving genetic and environmental factors. Because psoriasis is typically present for years before PsA-related joint symptoms emerge, dermatologists are in a unique position to detect PsA earlier in the disease process through regular, routine screening of psoriasis patients. Distinguishing clinical features of PsA include co-occurrence of psoriatic skin lesions and nail dystrophy, as well as dactylitis and enthesitis. Patients with PsA are usually seronegative for rheumatoid factor, and radiographs may reveal unique features such as juxta-articular new bone formation and pencil-in-cup deformity. Early treatment of PsA with disease-modifying anti-rheumatic drugs has the potential to slow disease progression and maintain patient quality of life. Optimally, a single therapeutic agent will control both the skin and joint psoriatic symptoms. A number of traditional treatments used to manage psoriasis, such as methotrexate and cyclosporine, are also effective for PsA, but these agents are often inadequately effective, temporary in benefit and associated with significant safety concerns. Biologic anti-tumour necrosis factor agents, such as etanercept, infliximab and adalimumab, are effective for treating patients who have both psoriasis and PsA. However, a substantial number of patients may lose efficacy, have adverse effects or find intravenous or subcutaneous administration inconvenient. Emerging oral treatments, including phosphodiesterase 4 inhibitors, such as apremilast, and new biologics targeting interleukin-17, such as secukinumab, brodalumab and ixekizumab, have shown encouraging clinical results in the treatment of psoriasis and/or PsA. Active and regular collaboration of dermatologists with rheumatologists in managing patients who have psoriasis and PsA is likely to yield more optimal control of psoriatic dermal and joint symptoms, and improve long-term patient outcomes.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3958815/bin/40265_2014_191_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3958815/bin/40265_2014_191_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3958815/bin/40265_2014_191_Fig3_HTML.gif)
Similar articles
-
ALIGN PsA: Advancing a Multidisciplinary Approach in PsA.Semin Cutan Med Surg. 2018 Dec;37(6S):S125-S134. doi: 10.12788/j.sder.2018.057. Semin Cutan Med Surg. 2018. PMID: 30605493 Review.
-
Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies.J Autoimmun. 2017 Jan;76:21-37. doi: 10.1016/j.jaut.2016.10.009. Epub 2016 Nov 9. J Autoimmun. 2017. PMID: 27836567 Review.
-
Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.BioDrugs. 2013 Aug;27(4):359-73. doi: 10.1007/s40259-013-0025-6. BioDrugs. 2013. PMID: 23580094 Review.
-
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. doi: 10.3310/hta10310. Health Technol Assess. 2006. PMID: 16948890 Review.
-
TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.BioDrugs. 2005;19(1):47-57. doi: 10.2165/00063030-200519010-00006. BioDrugs. 2005. PMID: 15691217 Review.
Cited by
-
Differences between psoriatic arthritis and psoriasis in multi-omics.Arch Dermatol Res. 2024 May 24;316(6):217. doi: 10.1007/s00403-024-03018-9. Arch Dermatol Res. 2024. PMID: 38787526 Review.
-
Circulating Immune Landscape Profiling in Psoriasis Vulgaris and Psoriatic Arthritis by Mass Cytometry.J Immunol Res. 2024 Apr 1;2024:9927964. doi: 10.1155/2024/9927964. eCollection 2024. J Immunol Res. 2024. PMID: 38590608 Free PMC article.
-
Endothelial dysfunction and risk factors for atherosclerosis in psoriatic arthritis: overview and comparison with rheumatoid arthritis.Rheumatol Int. 2024 Mar 24. doi: 10.1007/s00296-024-05556-x. Online ahead of print. Rheumatol Int. 2024. PMID: 38522049 Review.
-
From Psoriasis to Psoriatic Arthritis: Ultrasound Insights Connecting Psoriasis with Subclinical Musculoskeletal Inflammation and the Path to Psoriatic Arthritis.Curr Rheumatol Rep. 2024 Mar 21. doi: 10.1007/s11926-024-01146-9. Online ahead of print. Curr Rheumatol Rep. 2024. PMID: 38512585 Review.
-
Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis.Patient Prefer Adherence. 2023 Oct 3;17:2451-2461. doi: 10.2147/PPA.S427809. eCollection 2023. Patient Prefer Adherence. 2023. PMID: 37808274 Free PMC article.
References
-
- Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. - PubMed
-
- Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850. - PubMed
-
- Chang CA, Gottlieb AB, Lizzul PF. Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol. 2011;7(10):588–598. - PubMed
-
- Augustin M, Reich K, Glaeske G, et al. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147–151. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous